Abstract |
Diabetic patients have a markedly increased risk of cardiovascular disease compared with non-diabetics. Two drug groups today target insulin resistance; biguanides and thiazolidinediones. In addition, these may have other effects on cardiovascular risk factors. The aim of this study was to evaluate the effects of metformin and rosiglitazone on non-traditional cardiovascular risk factors. Forty type 2 diabetic patients were randomized into metformin and rosiglitazone groups. After receiving the optimal doses, the patients were monitored for 12 weeks. Biochemical parameters, lipid parameters, CRP, insulin, c-peptide, and HbA1c levels were analyzed. VWF, PAI-1, ICAM-1, TNF-α, IL-6, E-selectin, and fibrinogen levels were measured in order to assess coagulation status and endothelial dysfunction. In the metformin group, body mass index, PPG, HbA1c, IL-6, ICAM-1, and TNF-α levels were significantly decreased after 12 weeks compared with the basal levels. IL-6 levels decreased from 75 pg/ml ± 20 to 42 pg/ml ± 9 (P 0.023) and TNF- α levels from 61 pg/ml ± 31 to 39 pg/ml ± 10 (P 0.018). In the rosiglitazone group, FPG, PPG, HbA1c, insulin, HOMA-IR, IL-6, and TNF-α levels decreased significantly after 12 weeks compared with the basal levels. IL-6 levels decreased from 78 pg/ml ± 21 to 41 pg/ml ± 9 (P 0.028) and TNF-α levels from 62 pg/ml ± 19 to 37 pg/ml ± 10 (P 0.012). At the end of the study, no significant differences were determined between groups. Insulin resistance and type 2 diabetes are strongly associated with low grade inflammation. Both metformin and rosiglitazone were effective in controlling inflammatory markers in addition to metabolic parameters.
|
Authors | Evren Fidan, H Onder Ersoz, Mustafa Yilmaz, Hulya Yilmaz, Mustafa Kocak, Caner Karahan, Cihangir Erem |
Journal | Acta diabetologica
(Acta Diabetol)
Vol. 48
Issue 4
Pg. 297-302
(Dec 2011)
ISSN: 1432-5233 [Electronic] Germany |
PMID | 21424914
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- C-Peptide
- Interleukin-6
- Thiazolidinediones
- Tumor Necrosis Factor-alpha
- Rosiglitazone
- Metformin
|
Topics |
- Adult
- C-Peptide
(immunology)
- Cardiovascular Diseases
(epidemiology, etiology, immunology, physiopathology)
- Diabetes Mellitus, Type 2
(complications, drug therapy, metabolism)
- Endothelial Cells
(drug effects, immunology)
- Female
- Humans
- Interleukin-6
(immunology)
- Male
- Metformin
(therapeutic use)
- Middle Aged
- Rosiglitazone
- Thiazolidinediones
(therapeutic use)
- Tumor Necrosis Factor-alpha
(immunology)
|